Investment Analysts’ Recent Ratings Updates for Pfizer (PFE)

Several brokerages have updated their recommendations and price targets on shares of Pfizer (NYSE: PFE) in the last few weeks:

• 4/13/2026 – Pfizer had its price target raised by UBS Group AG from $25.00 to $27.00. They now have a “neutral” rating on the stock.
• 4/10/2026 – Pfizer had its price target raised by Morgan Stanley from $27.00 to $28.00. They now have an “equal weight” rating on the stock.
• 4/9/2026 – Pfizer had its price target lowered by Bank of America Corporation from $27.00 to $26.00. They now have a “neutral” rating on the stock.
• 3/24/2026 – Pfizer had its price target raised by Guggenheim from $35.00 to $36.00. They now have a “buy” rating on the stock.
• 3/17/2026 – Pfizer was given a new $27.00 price target by Morgan Stanley. They now have a “positive” rating on the stock.
• 3/17/2026 – Pfizer had its price target raised by HSBC Holdings plc from $29.00 to $32.00. They now have a “buy” rating on the stock.
• 3/9/2026 – Pfizer had its “outperform” rating reaffirmed by BMO Capital Markets. They now have a $30.00 price target on the stock.
• 3/2/2026 – Pfizer was upgraded by Argus from “hold” to “buy”. They now have a $35.00 price target on the stock.
• 2/24/2026 – Pfizer is now covered by Royal Bank Of Canada. They set an “underperform” rating and a $25.00 price target on the stock.
• 2/24/2026 – Pfizer was upgraded by Zacks Research from “strong sell” to “hold”.
• 2/19/2026 – Pfizer is now covered by Barclays PLC. They set an “underweight” rating and a $25.00 price target on the stock.

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.